



## Jessie Lee Ann Alexander

Clinical Associate Professor, Pediatrics - Stem Cell Transplantation

### CLINICAL OFFICE (PRIMARY)

- **Pediatric Stem Cell Transplantation**

725 Welch Rd Ste 160

Palo Alto, CA 94304

Tel (650) 497-8953 Fax (650) 497-8959

### Bio

---

#### CLINICAL FOCUS

- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Pediatrics - Stem Cell Transplantation
- Member, Maternal & Child Health Research Institute (MCHRI)

#### ADMINISTRATIVE APPOINTMENTS

- Medical Director, Stanford Pediatric Stem Cell Transplantation, (2025- present)

#### PROFESSIONAL EDUCATION

- Medical Education: Creighton University School of Medicine Registrar (2019) NE
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2017)
- Fellowship: St Jude Children's Research Hospital Bone Marrow Transplant and Cellular Therapy Fellowship (2016) TN
- Fellowship: University of Minnesota Pediatric Hematology/Oncology Fellowship (2015) MN
- Board Certification: Pediatrics, American Board of Pediatrics (2012)
- Residency: Stanford University Pediatric Residency at Lucile Packard Children's Hospital (2012) CA

### Research & Scholarship

---

#### CLINICAL TRIALS

- A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE), Recruiting
- CD4<sup>+</sup>LVFOXP3 in Participants With IPEX, Recruiting
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity, Recruiting
- Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab<sup>+</sup> T-cell/CD19<sup>+</sup> B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease, Not Specified

## Publications

---

### PUBLICATIONS

- **Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3.** *Journal of human immunity*  
Raves, A., Ramachandran, A., Pulsipher, M. A., Dolan, J. G., Cho, S., Johnson, A. K., Alexander, J. L., Borna, S., Bacchetta, R.  
2026; 2 (3): e20250249
- **Autologous Stem Cell Transplantation for Refractory Juvenile-Onset Systemic Sclerosis**  
Horvei, P., Li, J., Rosser, F., Rose-Felker, K., Alexander, J. L., Hogue, N., McIntyre, S., Koshy, L., Olson, A., Torok, K., Szabolcs, P.  
ELSEVIER SCIENCE INC.2026: S39-S40
- **Model-Based ATG Dosing Optimization in Ab Haplo-HSCT: Improved Pre-HSCT Exposure Consistency and Viral Infection Analysis**  
Shyr, D. C., Hiroshima, L., John, T. D., Barbarito, G., Agarwal, R., Alexander, J. L., Shah, A. J., Li, T., Chang, I., Arreola, V., Boelens, J., Bertaina, A.  
ELSEVIER SCIENCE INC.2026
- **Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report.** *Blood advances*  
Alexander, J. L., Dávila Saldaña, B. J., Brazauskas, R., Dammalapati, S. G., Griffith, L. M., Shah, A. J., Shimano, K. A., Ochs, H. D., Blessing, J.,  
Ebens, C. L., Kapadia, M., Bauchat, A., Kapoor, et al  
2025
- **Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.** *Blood advances*  
Raves, A., Logan, B. R., Liu, X., Dara, J., Buckley, R. H., Oved, J. H., Kapoor, N., Kapadia, M., Chandra, S., Martinez, C. A., Bunin, N.,  
Chandrakasan, S., Chen, et al  
2025
- **Marrow-ly we learn along: A needs assessment of the educational needs of pediatric and young adult patients with bone marrow failure**  
Bowman, S., de Jong, J., Alexander, J., Ilonze, C., Rose, M.  
ELSEVIER.2025: 2861-2862
- **Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)**  
Li, J., Horvei, P., Rosser, F., Rose-Felker, K., Sood, V., Olson, A., Vandergrift, V., Hogue, N., Farver, L., Mcguire, D., Havrilla, H., Alexander, J.,  
McIntyre, et al  
WILEY.2024: 4985-4988
- **Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)**  
Torok, K., Horvei, P., Rosser, F., Rose-Felker, K., Sood, V., Olsen, A., Hogue, N., Vandergrift, V., Farver, L., Mcguire, D., Li, J., Havrilla, H., Alexander,  
et al  
WILEY.2023: 5204-5206